2 claim verifications about Ozempic Ozempic ×
“Ozempic and similar GLP-1 drugs have contributed to a reduction in United States obesity rates for the first time in decades.”
U.S. adult obesity rates have indeed declined modestly — from roughly 42.8% (2017–2018) to about 40.3% (2021–2023) per CDC data, with Gallup surveys showing a further drop to ~37% by 2025. This coincides with a dramatic surge in GLP-1 drug use (30+ million Americans by 2025). Experts widely identify GLP-1 drugs as a plausible contributing factor, but no study has confirmed a direct causal link at the population level. The decline is also uneven — rural obesity actually rose — and other factors like post-COVID behavioral changes haven't been ruled out.
“The use of weight-loss drugs such as Ozempic and Wegovy will significantly impact public health outcomes by 2036.”
The claim is largely supported. High-quality peer-reviewed studies project that GLP-1 drugs like Ozempic and Wegovy could avert tens of thousands of deaths annually and prevent over a million cardiovascular events within the 2036 timeframe. Clinical efficacy is well-established, and early population-level signals are emerging. However, these projections depend on expanded access, sustained adherence, and affordability improvements that are not yet guaranteed — and high costs and coverage gaps could limit who benefits and worsen health disparities.